Table 2.
Changes in candidate biomarkers following six-months according to randomized assignment and the primary outcome of whether the participant lost 5% weight at six-months.
| Biomarker | Baseline Mean (SD) | 6-month Mean (SD) | Change in POWER-remote, Mean (SD), n | Change in Self-directed, Mean (SD), n | P-value* | Change in those who achieved >=5% weight loss (SD), n | Change in those who did not achieve >=5% weight loss (SD), n | P-value* |
|---|---|---|---|---|---|---|---|---|
| Adipocytokines (pg/mL) | ||||||||
| NGF | 0.5 (0.6) | 0.5 (0.6) | 0.06 (0.6), 44 | −0.03 (0.3), 41 | 0.2 | 0.06 (0.6), 27 | 0 (0.4), 58 | 0.6 |
| PA1 | 18295 (12836) | 19793 (15015) | 2138 (10685), 44 | 812.8 (6584), 41 | 0.3 | −887.3 (5102), 27 | 2609 (10068), 58 | 0.1 |
| MCP1 | 292.5 (144.1) | 327.9 (215.9) | 33.72 (156.2), 44 | 37.07 (232.4), 41 | 0.9 | 5.2 (129.5), 27 | 49.4 (219.2), 58 | 0.04 |
| HGF | 272.2 (158.8) | 327.5 (305.4) | 41(196.6), 44 | 70.76 (302.3), 41 | 0.60 | −35.6 (102.1), 27 | 97.7 (288.3), 58 | 0.02 |
| TNFα | 3 (2.7) | 3.4 (5.2) | 0.62(2.63), 44 | 0.31(7.73), 41 | 0.4 | 0.2 (3.06), 27 | 0.6 (6.55), 58 | 0.46 |
| IL1β | 0.8 (25) | 7. 8 (45.9) | 4.1 (22.4), 44 | 10.1 (62.4), 41 | 0.1 | −0.3 (1.25), 27 | 10.4 (55.52), 58 | <0.01 |
| IL6 | 4.6 (12.8) | 38.6 (259.9) | 9.7 (57), 44 | 60 (370.8), 41 | 0.6 | 0.7 (5.6), 27 | 49.5 (314.8), 58 | 0.5 |
| IL8 | 32.3 (158.2) | 206.2 (760.3) | 222.9 (905.2), 44 | 121.3 (601.6), 41 | 0.4 | 25.2 (221.1), 27 | 243.1 (915.6), 58 | 0.97 |
| Resistin | 35819 (66427) | 36672 (67715) | −7889 (71407), 44 | 10235 (40535), 41 | 0.6 | −4458 (83552), 27 | 3326 (43796), 58 | 0.27 |
| Leptin | 3582 (3761) | 3297 (3879) | −918.8 (2127), 44 | 395.1 (1596), 41 | <0.01 | −1615 (2388), 27 | 334 (1419), 58 | <0.01 |
| Adiponectin | 18304 (32062) | 19211 (27163) | 2662 (36375), 44 | −976.9 (36502), 41 | 0.7 | −2159 (34057), 27 | 2334 (37450), 58 | 0.3 |
| Metabolic panel (mg/dL) | ||||||||
| Insulin | 13 (7.9) | 12.4 (11.8) | −1.1 (10), 43 | −0.4 (7.8), 40 | 0.69 | −2.5 (5.2), 27 | 0.1 (10.3), 56 | 0.18 |
| Glucose | 90.1 (18) | 81.0 (29.4) | −9.6 (26.8), 43 | −8.8 (28.3), 40 | 0.43 | −1.6 (18.4), 27 | −12.8 (30.3), 56 | 0.24 |
| hs-CRP | 3.1 (3.2) | 4.6 (8.9) | 0.1 (2.6), 43 | 2.9 (10.6), 40 | 0.07 | −0.7 (1.6), 27 | 2.5 (9.1), 56 | <0.001 |
| Total cholesterol | 200.8 (35.6) | 200.4 (37.5) | −3.9 (18.2), 43 | 3.3 (25.5), 40 | 0.16 | −6 (17.5), 27 | 2.3 (23.8), 56 | 0.12 |
| Triglycerides | 127.4 (75.3) | 120.2 (68.8) | −11.1 (47.7), 43 | −3.1 (52.7), 40 | 0.77 | −24.3 (33.8), 27 | 1 (54.6), 56 | 0.02 |
| HDL | 61.7 (14.2) | 62.2 (13.7) | 1.3 (7.6), 43 | −0.3 (6.9), 40 | 0.42 | 1.5 (7.2), 27 | 0 (7.3), 56 | 0.41 |
| LDL | 113.7 (31.7) | 114.2 (31.7) | −2.8 (18.1), 43 | 4.2 (20.8), 40 | 0.14 | −2.4 (17.3), 27 | 2 (20.7), 56 | 0.51 |
| Total Cholesterol Ratio | 3.4 (1.1) | 3.4 (1.0) | −0.2 (0.5), 43 | 0.1 (0.5), 40 | 0.08 | −0.2 (0.4), 27 | 0 (0.5), 56 | 0.03 |
| Telomere length | −0.8 (0.8) | −0.7 (1.0) | 0.1 (0.7), 42 | 0.1 (0.7), 41 | 0.76 | 0 (0.5), 26 | 0.1 (0.8), 57 | 0.66 |
*
P values for Wilcoxon rank sum tests, comparing changes in biomarkers according to study arm and whether patients achieved the primary outcome for weight loss, are not adjusted for multiple comparisons and are included for descriptive purposes only.